Daptomycin safe, effective for pediatric cSSSI treatment


BY LUCAS FRANKIinPediatricson February 15th, 2017

FROM PEDIATRICS

Daptomycin was safe and effective at treating complicated skin and skin structure infections (cSSSI) in children aged 1-17 years, according to Dr. John Bradley of the University of California, San Diego, and his associates.

A total of 389 cSSSI patients were included in the study, with 257 receiving daptomycin and 132 receiving standard-of-care (SOC) treatment (mostly vancomycin or clindamycin). Clinical success rates were similar for both groups, at 91% in the daptomycin group and 87% in the SOC group. Therapeutic success rates also were similar, at 97% in the daptomycin group and 99% in the SOC group.

Adverse event incidence was similar in both groups, occurring in 14% of daptomycin patients and in 17% of SOC patients. The most common adverse events were diarrhea, occurring in 7% of daptomycin patients and 5% of SOC patients, and increased creatine phosphokinase, occurring in 6% of daptomycin patients and 5% of SOC patients.

“Daptomycin is a suitable once-daily alternative to vancomycin or clindamycin in the pediatric setting, particularly for suspected or confirmed MRSA [methicillin-resistant Staphylococcus aureus] infections,” the investigators concluded.

Find the full study in Pediatrics (doi: 10.1542/peds.2016-2477).

lfranki@frontlinemedcom.com

Source: http://www.mdedge.com/pediatricnews/article/131476/infectious-diseases/daptomycin-safe-effective-pediatric-csssi-treatment

Back to top